[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611568":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":27,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":24,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":24,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":24,"overallStatus":75,"whyStopped":24,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Jemincare","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX001899","EXPERIMENTAL","Orally, once daily",[13],"Drug: JMKX001899",{"label":15,"type":16,"description":17,"interventionNames":18},"Docetaxel","ACTIVE_COMPARATOR","By IV infusion every 21 days",[19],"Drug: Docetaxel",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"affiliation":30,"role":31},"Jie Wang, Doctor","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Fawei Wu","CONTACT","+86 15720614080","wufawei@jeyoupharma.com",[39],{"facility":30,"status":24,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Beijing","Beijing Municipality","100021","China","CN",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52],{"name":29,"role":35,"phone":53,"phoneExt":24,"email":54},"+86 13910704669","zlhuxi@163.com",{"type":56,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100611568","phase-3-phase-3-trial-of-jmkx001899-versus-docetaxel-in-previously-treated-advanced-or-metastatic-kras-g12c-mutant-nsclc-100611568",false,"NCT07242274","Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","A Multicenter, Randomized, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of JMKX001899 Versus Docetaxel in Previously Treated Patients With KRAS G12C-Mutant Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically or cytologically confirmed NSCLC.\n3. Failure of at least one prior line of therapy for locally advanced\u002Fmetastatic disease, that included a platinum-based chemotherapy and a PD-1\u002FPD-L1 inhibitor.\n4. At least one measurable lesion as defined by RECIST version 1.1.\n\nExclusion Criteria:\n\n1. Known concomitant presence of other oncogenic driver mutations or rearrangements with established targeted therapies .\n2. Previous treatment with any KRAS G12C-targeted agent.\n3. Prior docetaxel therapy in the locally advanced\u002Fmetastatic setting.","ALL","18 Years",{"count":67,"type":68},472,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","This is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic non-small cell lung cancer (NSCLC).\n\nKRAS G12C mutation is present in a subset of NSCLC patients. While docetaxel is a standard chemotherapy option, JMKX001899 is an investigational, targeted therapy designed to selectively inhibit the KRAS G12C mutation. This trial aims to determine whether JMKX001899 offers a superior clinical benefit compared to standard chemotherapy.",[74],"NSCLC (Non-small Cell Lung Cancer)","NOT_YET_RECRUITING","2025-11-17",{"date":78,"type":79},"2025-11-21","ACTUAL",{"date":81,"type":68},"2025-12-31",{"date":83,"type":68},"2029-12-30",{"name":5,"class":6},1]